Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. - Test2 - elhamkhani - TriplyDB

Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.

Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.

http://www.wikidata.org/entity/Q37822742

about

Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT.

P2860

Q38163027-D4EFB56A-3BF8-4B2E-8823-520587AAE373 Q53148090-857A75B0-8914-4D11-A198-3635EB1EDB55

P2860

Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.

http://www.wikidata.org/entity/Q37822742

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel agents to improve outcom ...... atients with multiple myeloma.

@en

Novel agents to improve outcom ...... atients with multiple myeloma.

@nl

type

label

Novel agents to improve outcom ...... atients with multiple myeloma.

@en

Novel agents to improve outcom ...... atients with multiple myeloma.

@nl

prefLabel

Novel agents to improve outcom ...... atients with multiple myeloma.

@en

Novel agents to improve outcom ...... atients with multiple myeloma.

@nl

P1433

Q37822742-556E8E65-478A-415A-BC27-C302A1CFFBC6

P1476

Q37822742-2B9B1E9F-9B5D-4AA5-9728-DD090DDB70CD

P2093

Q37822742-9CF91356-2E94-414D-B1C7-C604C1536F07

P2860

Q37822742-08AD09FF-144E-431E-BF86-112DCE862246

Q37822742-0DA70AB8-C6B9-45F6-98F4-FF0A8B0F843D

Q37822742-0FA0CDD2-D01D-409E-94A6-4A2A0386B15D

Q37822742-13FE0F91-2308-47DA-B855-A4CC42B9A1B7

Q37822742-18C874DA-6B62-47A5-9D65-0833968C8455

Q37822742-205CE091-7B0C-40BF-9FE5-2D88FBCF9846

Q37822742-24B157A2-2167-4527-89D5-398176331B92

Q37822742-24E9AEFD-B6BF-4768-9CA4-CC3F26EE0C65

Q37822742-25CDF288-820F-460C-BE9F-03471C5FFEEB

Q37822742-3007B611-CCC1-4C5E-9C82-8B094A92ACC8

P304

Q37822742-C34F5216-2864-4DCD-A43C-FE608291DD83

P31

Q37822742-24699843-ABC7-4DF1-A8E5-2B48B5BC85DD

Q37822742-405e0dd8-eb59-4aaa-8804-a3cd4520c1ec

P356

Q37822742-33CB7249-7FE8-437F-B232-402630E13B97

P407

Q37822742-8B2C7449-69F3-4FDE-AB72-52945CA64458

P433

Q37822742-92E1015C-8313-40AB-A811-ED10ADCD505A

P478

Q37822742-248F8255-FAFB-41F7-881A-B2D50E255B02

P50

Q37822742-B6EAB06F-2713-4E2E-804E-04EEF7DB18EE

Q37822742-B8764D41-0010-4B21-A109-BAC877C6499E

P577

Q37822742-E7190B7F-ED7F-442F-9736-939C57DA1084

P698

Q37822742-249EAA52-28BC-473E-AAC3-38238F51F98B

P356

P1433

Future Oncology

P1476

Novel agents to improve outcom ...... patients with multiple myeloma

@en

P2093

Stefan Knop

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

P304

135-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.10.162

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Hermann Einsele

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21174544

http://www.w3.org/2001/XMLSchema#string